Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | PPARA | Q07869 | 2/20 | 0.59 |
| ▸ | PPARG | P37231 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6378011 | 0.98 | SRD5A2 (0.63) | SRD5A2GAAL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6373824 | 0.91 | SRD5A2 (0.58) | SRD5A2GAAL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6375370 | 0.91 | SRD5A2 (0.58) | SRD5A2GAAL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24047115 | 0.89 | NR4A2 (0.73) | SRD5A2SMN1; SMN2POLBRAB9ANR4A1 | |
| SCHEMBL9618040 | 0.89 | GAA (0.74) | SRD5A2GAAL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12110127 | 0.87 | ALDH1A1 (0.57) | SRD5A2GAAL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6321328 | 0.87 | GAA (0.82) | SRD5A2GAAL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25686462 | 0.86 | NR4A1 (0.55) | SRD5A2GAAL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2984321 | 0.86 | MAOB (0.74) | GAAL3MBTL1ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL402300 | 0.85 | SRD5A2 (0.87) | SRD5A2GAAL3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1705169-A2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | Hormos Medical Ltd. (FI) | 2006-09-27 | — | — | EP | disclosed |
| EP-1235776-B1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORP (FI) | 2006-02-08 | — | — | EP | disclosed |
| US-6875775-B2 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD (FI) | 2005-04-05 | — | — | US | disclosed |
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | HORMOS MEDICAL OY LTD. | 2003-12-04 | — | — | US | disclosed |
| US-6576645-B1 | Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect | HORMOS MEDICAL OY LTD (FI) | 2003-06-10 | — | — | US | disclosed |
| EP-1235776-A1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Hormos Medical Corporation (FI) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001036360-A1 | TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | HORMOS MEDICAL CORPORATION (FI) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225130-A1 | Triphenylalkene derivatives and their use as selective estrogen receptor modulators | ESR2, ESR1, GPER1 | SRD5A2 92/4885GAA 4843/4885L3MBTL1 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.